NCT04184596已完成不适用
Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 153
- 试验地点
- 3
- 主要终点
- Patient preferences for topical and systemic pain treatment attributes
研究概览
简要总结
The objective of this study is to identify and weight attributes of topic and systemic pain treatment options relevant from the patients' perspective with peripheral neuropathic pain. The study will use a discrete choice experimental design to reach its objective.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosed peripheral neuropathic pain (pNP) as assessed by study sites
排除标准
- •Patients with no sufficient knowledge in written or oral German as assessed by study sites
结局指标
主要结局
Patient preferences for topical and systemic pain treatment attributes
时间窗: 20 minutes after survey start
Utility values obtained via multinominal logit estimates from discrete choice experiment
次要结局
- Relevance of attributes attributed with topical and systemic pain treatment(5 minutes after survey start)
- Marginal rate of substitution against pain reduction(20 minutes after survey start)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community HospitalsCancerNCT02559375Abramson Cancer Center at Penn Medicine466
尚未招募
不适用
Pain Types and Pain Severity in Chronic Low Back PainChronic Low-back PainNCT05604027Konya Beyhekim Training and Research Hospital200
尚未招募
不适用
Pain Types and Pain Severity in Chronic Neck PainChronic Neck PainNCT05581446Konya Beyhekim Training and Research Hospital200
招募中
不适用
Evaluation of the Perceived Experience of Patients Treated With Aligners With Two Different TimingsMalocclusionNCT06536335Fondazione Policlinico Universitario Agostino Gemelli IRCCS24
已完成
3 期
Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant PainPainNCT01167699Mundipharma Pharmaceuticals B.V.174
